Replimune Group Inc (OQ:REPL)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for REPL within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 24th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 24/20 Feb 20/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.04
Feb 14/20 Feb 12/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.03
Feb 14/20 Feb 12/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.04
Dec 23/19 Dec 20/19 Esposito Pamela Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -25,700  
Dec 23/19 Dec 20/19 Esposito Pamela Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 25,700 $1.75
Dec 11/19 Dec 9/19 Franchi Jean M. Direct Ownership Employee Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 180,000  
Dec 19/19 Nov 26/19 Kaufman Howard Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -58,067  
Dec 19/19 Nov 26/19 Kaufman Howard Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 58,067 $3.30
Nov 20/19 Nov 20/19 Atlas Venture Opportunity Fund I, L.P. Indirect Ownership Common Stock Form 3 : Initial Statement of Beneficial Ownership of Securities    
Nov 20/19 Nov 18/19 Rhodes Jason P Indirect Ownership Common Stock P - Open market or private purchase 1,100,000 $13.61
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for REPL within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 24th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 24/20 Feb 20/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.04
Feb 14/20 Feb 12/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.03
Feb 14/20 Feb 12/20 Coffin Robert Direct Ownership Common Stock S - Open market or private sale -24,250 $17.04
Dec 23/19 Dec 20/19 Esposito Pamela Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -25,700  
Dec 23/19 Dec 20/19 Esposito Pamela Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 25,700 $1.75
Dec 19/19 Nov 26/19 Kaufman Howard Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -58,067  
Dec 19/19 Nov 26/19 Kaufman Howard Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 58,067 $3.30
Dec 11/19 Dec 9/19 Franchi Jean M. Direct Ownership Employee Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 180,000  
Nov 20/19 Nov 18/19 Rhodes Jason P Indirect Ownership Common Stock P - Open market or private purchase 1,100,000 $13.61
Nov 20/19 Nov 20/19 Atlas Venture Opportunity Fund I, L.P. Indirect Ownership Common Stock Form 3 : Initial Statement of Beneficial Ownership of Securities    
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $REPL

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Alnylam Pharmaceuticals (OQ:ALNY)
Vir Biotechnology (OQ:VIR)